x

Search for a rare disease

* (*) mandatory field

Other search option(s)

Suggest an update

(*) Required fields.

Attention

Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. For all other comments, please send your remarks via contact us. Only comments written in English can be processed.

Orphanet doesn't provide personalised answers. To get in touch with the Orphanet team, please contact

Information provided in your contribution (including your email address) will be stocked in .CSV files that will be sent as an email to Orphanet's teams. These emails might be conserved in the teams' mailboxes, in our backoffice servers but will not be registered in our databases (for more information see our section General Data Protection Regulation and data privacy (GDPR) and Confidentiality).

Captcha image

Drug-induced autoimmune hemolytic anemia

Disease definition

Drug-induced autoimmune hemolytic anemia is a type of autoimmune hemolytic anemia (AIHA; see this term) that occurs as a reaction to therapeutic drugs, and can be due to various mechanisms.

ORPHA:90037

Classification level: Disorder
  • Synonym(s):
    • Drug-induced AIHA
  • Prevalence: <1 / 1 000 000
  • Inheritance: Multigenic/multifactorial 
  • Age of onset: All ages
  • ICD-10: D59.0
  • ICD-11: 3A20.Y
  • OMIM: -
  • UMLS: C0391817
  • MeSH: -
  • GARD: -
  • MedDRA: 10055213

Summary

Epidemiology

Drug-induced AIHA is rare; annual incidence is estimated at about 1/1,000,000. It is more common in adults and is very rare in children, although some fatal cases in children have been reported.

Clinical description

The disease presents with anemia linked to hemolysis, and physical examination may show an enlarged spleen.

Etiology

To date about 100 drugs have been implicated in drug-induced AIHA, including: cephalosporins (primarily cefotetan and ceftriaxone), levodopa, methyldopa, penicillin and its derivatives, quinidine and some nonsteroidal anti-inflammatory drugs.

Diagnostic methods

It is important to consider drug-induced AIHA when a patient serologically presents as either warm- or cold-type AIHA (see these terms) to avoid erroneous diagnosis.

Management and treatment

Stopping the drug that is causing the problem may relieve or control the symptoms. Patients may also be given IV immunoglobulin and prednisone to reduce the immune response. Blood transfusion may be needed in severe cases.

Prognosis

The prognosis is good if the causative drug is identified and the patient stops taking it. Death is a rare outcome, but has been reported particularly in children with AIHA caused by cefotetan and ceftriaxone.

Expert reviewer(s):  Pr Marc MICHEL - Last update: August 2010

  A summary on this disease is available in Deutsch (2010) Español (2010) Français (2010) Italiano (2010) Nederlands (2010) Português (2010)

Detailed information

General public

Guidelines

ERN produced/endorsed by ERN(s)   FSMR produced/endorsed by FSMR(s)

Additional information

Further information on this disease

Patient-centred resources for this disease

Research activities on this disease

Specialised Social Services

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.